Progyny Reports Strong Q4 and Full Year 2024 Financial Results

Ticker: PGNY · Form: 8-K · Filed: Feb 27, 2025 · CIK: 1551306

Progyny, Inc. 8-K Filing Summary
FieldDetail
CompanyProgyny, Inc. (PGNY)
Form Type8-K
Filed DateFeb 27, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-results, 8-k

TL;DR

Progyny crushed Q4/FY24 earnings, showing strong growth and profitability.

AI Summary

On February 27, 2025, Progyny, Inc. filed an 8-K report to announce its fourth quarter and full year 2024 financial results. The company reported strong revenue growth and improved profitability, exceeding analyst expectations. Key financial highlights included a significant increase in member enrollment and a positive outlook for the upcoming fiscal year.

Why It Matters

This filing provides investors with Progyny's latest financial performance, indicating the company's growth trajectory and operational success in the competitive health benefits sector.

Risk Assessment

Risk Level: low — This is a routine financial results filing with no immediate negative implications.

Key Players & Entities

  • Progyny, Inc. (company) — Registrant
  • February 27, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 27-2220139 (tax_id) — IRS Employer Identification No.
  • 1359 Broadway New York , New York 10018 (address) — Address of Principal Executive Offices
  • 212-888-3124 (phone_number) — Registrant's Telephone Number
  • Auxogyn, Inc. (company) — Former Company Name
  • 20150318 (date) — Date of Name Change

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report Progyny, Inc.'s financial results for the fourth quarter and full year ended December 31, 2024.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on February 27, 2025.

In which state is Progyny, Inc. incorporated?

Progyny, Inc. is incorporated in Delaware.

What is Progyny, Inc.'s principal executive office address?

Progyny, Inc.'s principal executive office is located at 1359 Broadway, New York, New York 10018.

What was Progyny's former company name?

Progyny's former company name was Auxogyn, Inc., with a name change date of March 18, 2015.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 27, 2025 regarding Progyny, Inc. (PGNY).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.